Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model

BOHUSLAV DVORAK,1,2 MELISSA D. HALPERN,1 HANA HOLUBEČ,3 CATHERINE S. WILLIAMS,1 DEBRA L. McWILLIAM,1 JESSICA A. DOMINGUEZ,1 RENATA STEPANKOVA,1 CLAIRE M. PAYNE,3 AND ROBERT S. MCCUSKEY1,2

1Department of Pediatrics and Steele Memorial Children’s Research Center, 3Department of Microbiology and Immunology, and 2Department of Cell Biology and Anatomy, University of Arizona, Tucson, Arizona 85724

Received 14 May 2001; accepted in final form 5 October 2001

Dvorak, Bohuslav, Melissa D. Halpern, Hana Holubec, Catherine S. Williams, Debra L. McWilliam, Jessica A. Dominguez, Renata Stepankova, Claire M. Payne, and Robert S. McCuskey. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol 282: G156–G164, 2002. First published October 10, 2001; 10.1152/ajpgi.00196.2001.—Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease of prematurely born infants. Maternal milk plays an important protective role against NEC development and is the major source of epidermal growth factor (EGF) for neonates. The aim of this study was to examine the effect of orally administered EGF on the incidence of NEC in a neonatal rat model. Newborn rats were artificially fed either with growth factor-free rat milk substitute (RMS) or RMS supplemented with 500 ng/ml of EGF (RMS+EGF). Experimental NEC was induced by exposure to asphyxia and cold stress. Development of NEC was evaluated by gross and histological scoring of damage in the ileum. Ileal EGF receptor (EGF-R), EGF, and transforming growth factor-α mRNA expression was assessed by RT-competitive-PCR, and the EGF-R was localized by immunohistochemistry. EGF supplementation of formula reduced the incidence and severity of NEC in rats (13/16 RMS vs. 4/13 RMS+EGF). Ileal EGF-R mRNA expression was markedly increased in the RMS group compared with RMS+EGF. Enhanced EGF-R expression in the RMS group was localized predominantly in the epithelial cells of injured ileum. These data suggest a new potential therapeutic approach for the prevention and treatment of NEC.

intestinal injury; inflammation; neonatal intestine; artificial feeding

NEONATAL NECROTIZING ENTEROCOLITIS (NEC) is the most common gastrointestinal (GI) disease of premature infants affecting 3,000–5,000 neonates in the US each year (31). Prematurity, enteral feeding, bacterial colonization, and intestinal hypoxia-ischemia are considered the major risk factors for the development of this disease (6). In spite of extensive epidemiological, clinical, and basic research, the pathogenesis of NEC is unknown and there is no effective preventative treat-
NEC-like symptoms was successfully treated by continuous intravenous infusion of EGF (51).

The aim of the present study was to test the effects of enteral administration of EGF on the development of NEC in neonatal rats. Our hypotheses were that enteral administration of EGF would reduce the development and incidence of neonatal NEC and that the healing effect of EGF would be mediated through interaction with the EGF-R at the site of intestinal injury. We induced experimental NEC in neonatal rats using artificial formula feeding coupled with exposure to asphyxia/cold stress (2, 5). We evaluated the effects of enteral administration of EGF on the development and incidence of NEC, gene expression and cellular localization of EGF-R at the site of injury, and changes in ileal endogenous synthesis of two major EGF-R ligands: EGF and transforming growth factor (TGF)-α peptides.

MATERIALS AND METHODS

Animal model and diets. The study protocol was approved by the Animal Care and Use Committee of the University of Arizona (A-324801-95081). Sixty Sprague-Dawley neonatal rats (Charles River Labs, Portage, MI), originating from nine different litters, were used in three separate experiments. Newborn rats were collected from their mothers immediately after birth to prevent suckling of maternal milk. Animals were weighed and then placed in an infant incubator to control body temperature and assigned to three experimental groups: artificially fed with growth factor-free rat milk substitute (RMS), artificially fed with RMS supplemented with 500 ng/ml rat EGF (Harlan Bioproducts, Indianapolis, IN) (RMS + EGF), or littermates fed by their mothers (dam fed). In addition, nonstressed dam fed littermates served as physiological controls in these studies. To develop clinical and pathological signs of NEC, rat pups from all three experimental groups were stressed by gentle stimulation of the anogenital region and mixed. The appearance and intensity of any blue or blue-green color was evaluated within 1 to 5 min and scored on a scale of 0–4 by two independent, blinded evaluators. Each blue color appearing within 1 min was graded 4. Lower degrees of color development occurring within 1–5 min were graded 1–3 (3, strong signal; 2, moderate signal; 1, small traces of blue in stools). No blood in stools (no color development) was scored as 0. To minimize the variability in analysis of grading, a no-blood sample (0) and a systemic blood sample (4) were assayed as a standard range.

DNA and protein measurements. Tissue DNA and protein content were measured as described previously (13). Briefly, total DNA content in the ileum was assayed by the diphenylamine method of Burton (4) and determined by spectrophotometry. Assays for total protein content in the ileum (26) were determined by spectrophotometry (SPECTRAMax PLUS, Molecular Devices, Sunnyvale, CA).

Immunohistology of the EGF-R. Samples of distal ileum (2–3 cm) were fixed overnight in 70% ethanol, processed, paraffin embedded, and microtome sectioned at 4–6 μm. Sections were deparaffinized in xylene and rehydrated in serial dilutions of 50–100% ethanol and water. Antigen unmasking was achieved using 0.05% saponin (Sigma, St. Louis, MO) for 30 min, followed by blocking of endogenous peroxidase using 0.1% hydrogen peroxide for an additional 30 min. Sections were blocked with 1.5% goat serum (Vector Laboratories, Burlingame, CA) in PBS for 30 min, then incubated with 1 μg/ml rabbit anti-EGF-R polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min, washed with PBS three times, and incubated with a biotinylated goat anti-rabbit secondary antibody (Vector Laboratories) for 30 min. After three PBS washes, the Vectastain Elite ABC reagent (Vector Laboratories) was applied for 30 min, slides were washed three times with PBS, then diaminobenzene (Sigma) was utilized as the substrate. Sections were then counterstained with hematoxylin, dehydrated, and coverslipped (58). Control sections were treated with the same procedure except that they were incubated with 5 μg/ml rabbit Ig (Sigma) instead of the anti-EGF-R antibody. No staining was detected in control slides. Sections from all three experimental groups were stained for EGF-R at the same time, and stained sections were evaluated by a blinded observer.

Total RNA was isolated from tissue using the RNeasy mini kit (Qiagen, Santa Clarita, CA) as described in the manufacturer’s protocol. All samples were incubated with RNase-free DNase (20 U/reaction) for 10 min at 37°C to eliminate DNA contamination. RNA concentration was quantified by ultraviolet spec-
trophotometry at 260 nm ($A_{260}$) and the purity was determined by the $A_{260}/A_{280}$ ratio (SPECTRAmax PLUS, Molecular Devices). The integrity of RNA samples was verified by electrophoresis on 1.2% agarose gel containing formaldehyde (2.2 M) and ethidium bromide in 1× MOPS buffer [40 mM MOPS (pH 7.0), 10 mM sodium acetate, and 1 mM EDTA (pH 8.0)]. The RT competitive-PCR assay was used to quantify intestinal EGF-R, EGF, and TGF-α mRNA levels as previously described in detail (12, 15).

Statistics. Statistical analysis of the results was performed by one-way ANOVA followed by Fisher’s protected least significant difference using the statistical program StatView for Macintosh computers (Abacus Concepts, Berkeley, CA). A value of $P < 0.05$ was considered significant at the 95% confidence level. All data in the figures are means ± SE.

RESULTS

Effects of EGF on body weight gain and ileal parameters. Body weights in the RMS group gradually decreased during the study period, whereas rats fed RMS+EGF were able to maintain the same body weight during the same time period (Fig. 1). Differences in body weight between RMS and RMS+EGF groups were statistically significant at 72 h ($P < 0.05$), with the difference increasing by 96 h ($P < 0.01$). Dam fed pups showed steady increases in body weight throughout the experiments. There were no differences in body weight gain of pups in the asphyxia/cold stressed dam fed group compared with their non-stressed dam fed littermates (results not shown). Ileal protein content was similar in all three experimental groups (Table 1). DNA content was significantly higher in dam fed rats compared with both RMS and RMS+EGF groups, but there was no statistical difference between the RMS and the RMS+EGF groups (Table 1). Effects of EGF on the incidence of NEC. Animals developed visual signs characteristic of intestinal injury between 72 and 96 h after the beginning of the experiments. These signs included abdominal distention, discoloration of the abdominal wall, and occult blood in the stool. Because progression of intestinal damage typically resulted in death, we performed guaiac measurements at 72 rather than 96 h. Results from these measurements are summarized in Table 1. The RMS group exhibited a significantly stronger signal ($P < 0.0001$) for the presence of blood in the stool compared with the RMS+EGF group. Dam fed animals had no or minimal blood in the stool.

Macroscopic and microscopic examination of the GI tract showed clear evidence of intestinal damage similar to neonatal NEC. Macroscopically, the jejenum and ileum exhibited severe inflammation, hemorrhage, and discoloration (Fig. 2). The degree of damage varied from pink/red to dark purple/black discoloration in NEC rats (Fig. 2B) compared with the yellow/green appearance of normal gut from healthy rat pups (Fig. 2A). The ileum was generally more severely affected than the jejunum; typical intestinal distention and stenosis were located predominantly in ileum (Fig. 2B, detail). In addition, luminal contents of the ileum were dark and bloody. In animals with moderate progression of NEC, pathological changes in the small bowel were patchier, with scattered areas of hemorrhage, distention, and stenosis in the ileum. Histological analyses of ileal segments were performed using a scoring system from 0 to 4+ (Fig. 3) to determine the severity of NEC. Results from these measurements are shown in Fig. 4. In the RMS group, histological findings in most animals showed significant pathological changes in ileal structure (mean NEC score = 2.6). The degree of ileal damage was significantly reduced ($P < 0.001$) in rats fed with RMS+EGF (mean NEC score = 1.3) compared with the RMS group. Dam fed pups showed no or minimal pathological changes in ileal morphology (mean NEC score = 0.43). Comparison of the overall incidence of NEC revealed that 81% of RMS pups developed significant intestinal abnormalities described as moderate, severe, or full necrosis. Supplementation of EGF into formula resulted in a dramatic, 50% reduction in the incidence of NEC. Dam fed animals showed no changes or abnormalities in the small intestinal structure resembling the development of NEC (Table 2).

Table 1. Ileal protein and DNA content and blood in stool values

<table>
<thead>
<tr>
<th></th>
<th>Dam Fed</th>
<th>RMS</th>
<th>RMS+EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>10</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Protein, mg/g of tissue</td>
<td>$108.4 \pm 6.6$</td>
<td>$95.5 \pm 4.5$</td>
<td>$102.4 \pm 4.6$</td>
</tr>
<tr>
<td>DNA, mg/g of tissue</td>
<td>$6.0 \pm 0.3$</td>
<td>$5.0 \pm 0.2$</td>
<td>$5.0 \pm 0.3$</td>
</tr>
<tr>
<td>Protein:DNA ratio</td>
<td>$18.4 \pm 1.4$</td>
<td>$19.2 \pm 1.1$</td>
<td>$21.2 \pm 1.7$</td>
</tr>
<tr>
<td>Blood in stool</td>
<td>$0.2 \pm 0.1$</td>
<td>$3.3 \pm 0.3$</td>
<td>$1.3 \pm 0.4$</td>
</tr>
</tbody>
</table>

Values are means ± SE; $n =$ no. of animals. Stool analysis: 0, no blood in stools; 1, small traces of blood; 2, moderate presence of blood; 3, strong signal for the presence of blood; 4, very strong signal for the presence of blood. Mean values within a row not sharing a common superscript letter were significantly different ($P < 0.01$, ANOVA).
Ileal EGF-R, EGF, and TGF-α mRNA levels. To evaluate changes in gene expression of the EGF-R, ileal steady-state mRNA levels were measured using RT competitive-PCR (Fig. 5A). Ileal EGF-R mRNA levels were markedly increased (~7- to 8-fold) in the RMS group compared with the dam fed group. Supplementation of the RMS diet with EGF was associated with a statistically significant decrease in ileal EGF-R content compared with RMS alone (P < 0.01), with the mRNA level in this group intermediate between the mRNA levels of dam fed and RMS fed rats. There was no difference in the EGF-R mRNA level between dam fed and nonstressed dam fed littersmates (results not shown). Changes in endogenous synthesis of two major EGF-R ligands, EGF and TGF-α, revealed no statistically significant changes in either EGF and TGF-α mRNA levels in the ileum of RMS animals compared with either RMS+EGF or dam fed pups (Fig. 5, B and C).

Histological localization of the EGF-R. Histological examination of ileal samples from dam fed pups revealed low levels of EGF-R expression in the apical and basolateral membranes of the villi (Fig. 6A and D). The pattern of EGF-R localization in the RMS group was similar to that seen in dam fed animals, except that there was very strong staining of the apical membrane and moderate staining of the basolateral membrane of the villi enterocytes (Fig. 6B and E). In contrast, animals given RMS+EGF had markedly decreased expression of the EGF-R in the apical and basolateral membranes of the villi compared with the RMS group (Fig. 6C and F).
DISCUSSION

Our present study provides, for the first time, evidence that enteral administration of EGF reduces the development and the incidence of NEC in a neonatal rat model. Moreover, the increased expression of EGF-R in damaged ileum indicates that the healing effect of exogenous EGF is mediated directly at the site of intestinal injury. Interestingly, the development of NEC has no effect on the endogenous production of EGF and TGF-α ligands in damaged ileum.

NEC is a disease of premature babies. The reasons for a predilection for prematurity are unclear, but an immature mucosal barrier and immune response likely contribute to the premature neonates’ susceptibility. Amniotic fluid concentrations of EGF gradually increase during pregnancy, with the highest level achieved at the end of the normal gestation period (22). EGF is also present in high concentrations in colostrum and breast milk of many mammalian species (25, 34), and during the suckling period, milk-borne EGF is the major source of EGF for the developing neonate (42). In contrast, EGF is absent in all commercial formulas. In suckling animals, supplementation of EGF into formula enhances the growth of stomach and the small intestine (3), induces precocious maturation of intestinal brush-border disaccharidase activities (32), and modulates intestinal nutrient transport (33). Because the incidence of NEC is, in the majority of

Table 2. Effect of enteral EGF on incidence of NEC in neonatal rat model

<table>
<thead>
<tr>
<th>NEC Positive* / Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dam Fed</td>
</tr>
<tr>
<td>RMS</td>
</tr>
<tr>
<td>RMS + EGF</td>
</tr>
<tr>
<td>0/7</td>
</tr>
<tr>
<td>13/16</td>
</tr>
<tr>
<td>4/13</td>
</tr>
<tr>
<td>% NEC</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>81</td>
</tr>
<tr>
<td>31</td>
</tr>
</tbody>
</table>

EGF, epidermal growth factor; NEC, necrotizing enterocolitis. To compare the incidence of NEC from all conducted studies, animals with ileal changes histologically scored ≥2+ were considered NEC positive. The definition for each histological grade was as follows: normal (0), no damage; mild (1+), slight submucosal and/or lamina propria separation; moderate (2+), moderate separation of submucosa and/or lamina propria, edema in submucosal and muscular layers; severe (3+), severe separation of submucosa and/or lamina propria, severe edema in submucosal and muscular layers, regional villi sloughing; and full necrosis (4+), loss of villi and necrosis.

Fig. 4. Mean NEC scores from ileal tissue from dam fed (n = 10), RMS (n = 16), and RMS + EGF (n = 13) neonatal rats. Values are means ± SE from histological scoring. *P < 0.001 RMS vs. dam fed rats; #P < 0.001 dam fed vs. RMS rats.

Fig. 5. Expression of EGF receptor (EGF-R; A), EGF (B), and transforming growth factor (TGF)-α (C) mRNA in the ileum of dam fed, RMS, and RMS + EGF neonatal rats. Steady-state mRNA levels were quantified using RT competitive-PCR; n = 10–15 samples per group. *P < 0.001 RMS vs. dam fed rats; #P < 0.001 dam fed vs. RMS rats.
cases, related to formula feeding of newborn babies, we proposed that the absence of EGF in developing gut increases the potential to develop this disease. Results from the present study support this hypothesis and suggest a critical role of milk-borne EGF in the maintenance of gut integrity and healthy development.

The first report relating EGF and intestinal necrosis was reported in England, where an 8-mo-old child with intestinal necrosis similar to NEC was successfully treated with continuous infusion of EGF (51). Scott et al. (46) have shown significant elevation of urinary EGF levels in neonates diagnosed with NEC that they suggest might result from increased absorption of EGF through the damaged intestinal mucosa. Furthermore, markedly diminished serum and salivary EGF levels have been reported in premature infants with NEC (19, 48). These data suggest that administration of exogenous EGF may provide an effective means to prevent or treat this disease. In this study, we demonstrate that the supplementation of milk formula with EGF markedly reduces the development and severity of NEC. The importance of this finding is particularly significant because EGF was given orally. The use of growth factors for the treatment of GI disease is always associated with concerns over their potential risks. Systemically administered growth factors could induce proliferation in other regions of the body that harbor premalignant cells (34). Thus enteral administration of EGF enables use of a higher dose of EGF and helps deliver growth factor directly into the site of intestinal injury. Rat milk contains 30–50 ng/ml EGF (43, 55). Our preliminary study has indicated that supplementation of formula with a physiological dose of EGF (100 ng/ml) has markedly lower efficiency in the prevention and severity of NEC (data not shown). In addition, maternal milk contains a variety of proteins, such as casein, that can act as competitive substrates for proteolytic enzymes and specific proteolytic inhibitors that can protect luminal peptide growth factors from degradation (35, 38). Moreover, intestinal proteolytic activity is significantly lower in the early postnatal period compared with adulthood (20). Therefore, supplementation of a higher dose of EGF into milk formula can protect EGF against this inherent proteolytic degradation in the stomach and small intestine and improve
the efficiency of injury treatment during the perinatal period of life.

The mechanisms underlying the protective effects of EGF in injured mucosa are not clearly understood. However, the involvement of the EGF-R in the biological action of EGF has been extensively studied (8). The presence of EGF-R in human fetal intestine was first demonstrated in crypt cells, epithelial cells at the base of the villus, and the inner circular layer of the intestinal muscle (37). In rats, EGF-R expression was detected throughout the entire small intestine (39) and localized originally to the basolateral membrane of the crypt and villus epithelium only (44, 53, 54). However, recent studies have shown the presence of EGF-R also on the apical membrane of villus epithelium in rats (29) and rabbits (56). Indeed, results from our study indicate that in neonatal rats, low expression of EGF-R is localized in both apical and basolateral membrane of ileal enterocytes. In addition, during mucosal injury EGF-R localization and expression in intestinal mucosa is changed. In mice and rats that have undergone small bowel resection, an increase in EGF-R production and increased receptor activation was noted (47, 57). Increased EGF-R production was reported in epithelial cells of the ulcer margins (59) with EGF-R expression localized on the basolateral and apical surfaces (52). These results indicate that during mucosal injury, the EGF-R can effectively be reached by its ligands (EGF or TGF-α) from the luminal side. In addition, during the early postnatal period high intestinal permeability enables rapid transport of EGF across the jejunal epithelium (39) and therefore EGF-R on the basolateral side of the epithelium can be reached as well. Our results complement the findings of these previous studies. Gene expression of EGF-R at the site of injury (distal ileum) is increased, and treatment with orally administered EGF downregulates EGF-R mRNA levels toward normal levels. The presence of EGF-R in NEC tissues is localized predominantly in the apical and basolateral membranes of the villi enterocytes, whereas in healthy tissue EGF-R is minimally detected. Changes in EGF-R expression are observed as soon as 24 h after asphyxia/cold stress exposure, before any histopathological changes in intestinal architecture can be detected (data not shown). Together, these data support the idea that the EGF-R belongs to an essential defense mechanism of intestinal epithelial integrity wherein peptide growth factors such as EGF or TGF-α play critical protective and healing roles (34, 36).

In suckling rats, intestinal contents of EGF and TGF-α peptides are similar but the origins are different. The major source of intestinal EGF is maternal milk (42). TGF-α, however, is not detectable in rat milk, and its intestinal content is likely the result of endogenous synthesis by the small intestine and pancreatic secretion (11). Recently, we have shown that endogenous intestinal EGF and TGF-α production can be regulated nutritionally in suckling rats. Feeding growth factor-free RMS diet for 4 days to neonatal rats resulted in significant increases of TGF-α and EGF mRNA levels in the developing duodenum and ileum (15). Studies have shown increased mucosal TGF-α expression in adult rabbits (49) and rats (21) with experimental colitis. Mice lacking TGF-α exhibited increased susceptibility to dextran sulfate-induced colitis (17), whereas mice overexpressing TGF-α had markedly decreased susceptibility to experimentally induced colitis (16). Our current observations that ileal EGF and TGF-α mRNA levels were unaffected by either NEC injury or EGF treatment may indicate that highly immature intestinal tissue does not have the potential to initiate the reparative process by increased endogenous production of EGF-R ligands.

In the present study, we have shown that oral administration of EGF has beneficial effects in the prevention of NEC in an experimental rat model. Supplementation of commercial milk formula with recombinant EGF to stimulate intestinal repair processes may significantly reduce the incidence of neonatal NEC in prematurely born neonates and suggests new therapeutic approaches in the treatment of GI diseases of pediatric patients.

We thank Dr. Anthony F. Philippi for editing the manuscript. Current address for R. Stepankova: The Academy of Sciences of the Czech Republic, Institute of Microbiology, Novy Hradec, Czech Republic.

This work was supported by National Institute of Child Health and Human Development Grants HD-26013 and HD-39657 (to B. Dvorak), the University of Arizona Vice President for Research and Graduate Students Award (to B. Dvorak), and the Grant Agency of the Czech Republic 303/00/1370 (to R. Stepankova).

REFERENCES


